Treating bipolar depression with standard antidepressants has long been controversial, because some patients do not respond and it is believed that the drugs trigger manic episodes. Two physicians ...

The US Food and Drug Administration (FDA) has approved lurasidone (Latuda, Sunovion Pharmaceuticals), already indicated for schizophrenia, to treat major depressive episodes in adults with bipolar 1 ...

Discover comprehensive details about Lurasidone, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — Positive results were found in two pivotal safety and efficacy studies that looked at lurasidone ...

December 15, 2009 (Hollywood, Florida) — Lurasidone, a serotonin dopamine antagonist, effectively treats symptoms of schizophrenia with few adverse metabolic effects, including weight gain, according ...

Nora Pharma's Lurasidone is available in strengths of 20 mg, 40 mg, 60 mg, and 80 mg and comes in bottles of 30 tablets. According to Verified Market Reports, the global market size of Lurasidone was ...

In June 2013, the FDA expanded its indication for the antipsychotic lurasidone, marketed as Latuda, for use in bipolar disorder, either as a monotherapy or in combination with lithium or valproate.

Up to 20 weeks of treatment with lurasidone adjunctive to lithium or valproate in patients with bipolar I disorder resulted in a "clinically significant mean improvement in depression and mania scores ...

MARLBOROUGH, Mass. -- Sunovion Pharmaceuticals Inc. (Sunovion) today announced that Latuda® (lurasidone HCl) tablets, a once-daily atypical antipsychotic agent indicated for the treatment of adult ...

Review the side-effects of Lurasidone as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

The FDA has approved two new indications for the atypical antipsychotic drug lurasidone in the treatment of adult patients with major depressive episodes associated with bipolar I disorder, according ...

FORT LAUDERDALE, F / ACCESS Newswire / May 6, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of ...